nach oben

The journal of nutrition, health & aging

Erschienen in:

17.09.2022 | Original Research

Prevalence and Associates of Frailty Status in Different Stages of Chronic Kidney Disease: A Cross-Sectional Study

verfasst von: S. Ozturk, D. G. Cetin, M. Cetin, M. D. Yilmaz, T. E. Ozler, E. Cebeci, S. Karadag, H. Feyizoglu, Gulistan Bahat

Erschienen in: The journal of nutrition, health & aging | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Frailty is a state of homeostenosis associated with adverse outcomes. Chronic kidney disease (CKD) increases considerably by aging and shares the common risk factors with frailty. We aimed to examine the prevalence and independent associates of frailty status in CKD patients.

Design

In this single-centre, cross-sectional study, we used the five-item Fatigue, Resistance, Ambulation, Illnesses and Loss of Weight (FRAIL) scale to evaluate frailty. A binary logistic regression analysis model including the parameters found to have relationship with frailty in univariate analyses was used to detect independent associates of frailty status. Odds ratio (OR) and 95% confidence interval (CI) were given.

Participants

Study included 148 patients aged 18–80. Sixty (60) patients were end stage renal disease (ESRD) patients on maintenance hemodialysis (HD) (at least for 3 months) and 88 were stage 3–4 CKD patients. Thirty-seven (37) patients (42%) were eGFR G3a, 31 patients (35.3%) were eGFR G3b and 20 patients (22.7%) were eGFR G4 in stage 3–4 CKD patients.

Measurements

Demographics, etiology of CKD, comorbidities, regular drugs, dialysis-related and laboratory data were recorded. FRAIL scale was scored as follows; 0=robust, 1–2=prefrail, and ≥3=frail. The frailty status was compared between frail+prefrail group vs robust (non-frail) group.

Results

The prevalences of prefrailty and frailty were 68.3% and 3.3% in HD group and 53.4% and zero in stage 3–4 CKD group, respectively (p = 0.025). In the multivariate logistic regression analysis, being in HD group (OR=3.87, 95% CI= 1.06–14.19, p=0.04), older age (OR=1.09, 95% CI= 1.04–1.13) and female sex (OR=9.13, 95% CI= 2.82–29.46) were independent risk factors for frailty (p<0.001, for both).

Conclusion

Prefrailty and frailty are quite common among HD and CKD stage 3–4 patients. Being an HD patient is an independent risk factor for non-robust (frail or prefrail) status. Our findings point out a remarkably high prevalence of frailty severity (prefrailty/frailty) phenotype among patients with advanced CKD stages.

Nascimento C, Ingles M, Salvador-Pascual A, Cominetti M, Gomez-Cabrera M, Viña JJFRB, et al. Sarcopenia, frailty and their prevention by exercise. 2019;132:42–9.

Hosam KKJNR. Sarcopenia and aging. 2003;61(51):157–67.doi: https://doi.org/10.1301/nr.2003.may.157-167.

Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. 2006;54(6):991–1001.doi:https://doi.org/10.1111/j.1532-5415.2006.00745.x.

Drost D, Kalf A, Vogtlander N, van Munster BC JIu, nephrology. High prevalence of frailty in end-stage renal disease. 2016;48(8):1357–62.doi: https://doi.org/10.1007/s11255-016-1306-z.

Ali H, Abdelaziz T, Abdelaal F, Baharani JJS JoKD, Transplantation. Assessment of prevalence and clinical outcome of frailty in an elderly predialysis cohort using simple tools. 2018;29(1):63.doi: https://doi.org/10.4103/1319-2442.225175.

Wang XH, Mitch WEJNRN. Mechanisms of muscle wasting in chronic kidney disease. 2014;10(9):504–16.doi: https://doi.org/10.1038/nrneph.2014.112.

Yabuuchi J, Ueda S, Yamagishi S-i, Nohara N, Nagasawa H, Wakabayashi K, et al. Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. 2020;10(1):1–12.doi: https://doi.org/10.1038/s41598-020-74673-x.

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. 2001;56(3):M146–M57.doi: https://doi.org/10.1093/gerona/56.3.m146.

Theou O, Cann L, Blodgett J, Wallace LM, Brothers TD, Rockwood KJ Arr. Modifications to the frailty phenotype criteria: Systematic review of the current literature and investigation of 262 frailty phenotypes in the Survey of Health, Ageing, and Retirement in Europe. 2015;21:78–94.doi: https://doi.org/10.1016/j.arr.2015.04.001.

10.

Bahat G, Ilhan B, Tufan A, Dogan H, Karan MJTjon, health, aging. Success of simpler modified fried frailty scale to predict mortality among nursing home residents. 2021;25(5):606–10.doi: https://doi.org/10.1007/s12603-020-1582-2.

11.

Morley JE, Malmstrom T, Miller DJTjon, health, aging. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. 2012;16(7):601–8.doi: https://doi.org/10.1007/s12603-012-0084-2.

12.

Gardiner PA, Mishra GD, Dobson AJ JJotAMDA. Validity and responsiveness of the FRAIL scale in a longitudinal cohort study of older Australian women. 2015;16(9):781–3.doi: https://doi.org/10.1016/j.jamda.2015.05.005.

13.

Thompson MQ, Theou O, Tucker GR, Adams RJ, Visvanathan RJAJoA. FRAIL scale: Predictive validity and diagnostic test accuracy. 2020;39(4):e529–e36.doi: https://doi.org/10.1111/ajag.12829.

14.

Jung H-W, Yoo H-J, Park S-Y, Kim S-W, Choi J-Y, Yoon S-J, et al. The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly. 2016;31(3):594.doi:https://doi.org/10.3904/kjim.2014.331.

15.

Aprahamian I, de Castro Cezar NO, Izbicki R, Lin SM, Paulo DLV, Fattori A, et al. Screening for frailty with the FRAIL scale: a comparison with the phenotype criteria. 2017;18(7):592–6.doi: https://doi.org/10.1016/j.jamda.2017.01.009.

16.

Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al. Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association with mortality. 2015;30(10):1718–25.doi: https://doi.org/10.1093/ndt/gfv133.

17.

Moreno-Gonzalez R, Corbella X, Mattace-Raso F, Tap L, Sieber C, Freiberger E, et al. Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria. 2020;20(1):1–12. doi: https://doi.org/10.1186/s12877-020-01700-x.

18.

Souza VAd, Oliveira D, Barbosa SR, Corrêa JOdA, Colugnati FAB, Mansur HN, et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. 2017;12(4):e0176230.doi: https://doi.org/10.1371/journal.pone.0176230.PubMedPubMedCentral

19.

D’alessandro C, Piccoli GB, Barsotti M, Tassi S, Giannese D, Morganti R, et al. Prevalence and correlates of sarcopenia among elderly CKD outpatients on tertiary care. 2018;10(12):1951.doi: https://doi.org/10.3390/nu10121951.

20.

Zhou Y, Hellberg M, Svensson P, Höglund P, Clyne NJNDT. Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3–5. 2018;33(2):342–8.doi: https://doi.org/10.1093/ndt/gfw466.

21.

Lai S, Muscaritoli M, Andreozzi P, Sgreccia A, De Leo S, Mazzaferro S, et al. Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy. 2019;62:108–14.doi: https://doi.org/10.1016/j.nut.2018.12.005.

22.

Vandenbroucke JPJAIM. Elm E von, Altman DG et al. for the STROBE Initiative (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.147:W163–W94.doi:https://doi.org/10.1016/j.ijsu.2014.07.014.

23.

Dent E, Kowal P, Hoogendijk EOJEjoim. Frailty measurement in research and clinical practice: a review. 2016;31:3–10.doi: https://doi.org/10.1016/j.ejim.2016.03.007.

24.

Bahat Öztürk G, Kiliç C, Bozkurt M, Karan MJTjon, health, aging. Prevalence and associates of fear of falling among community-dwelling older adults. 2021;25(4):433–9. doi: https://doi.org/10.1007/s12603-020-1535-9.

25.

Delibaş DH, Eşkut N, İlhan B, Erdoğan E, Top Karti D, Yilmaz Küsbeci Ö, et al. Clarifying the relationship between sarcopenia and depression in geriatric outpatients. 2021;24(1):29–36.doi: https://doi.org/10.1080/13685538.2021.1936482.

26.

McAdams-DeMarco MA, Tan J, Salter ML, Gross A, Meoni LA, Jaar BG, et al. Frailty and cognitive function in incident hemodialysis patients. 2015;10(12):2181–9.

27.

Alfaadhel TA, Soroka SD, Kiberd BA, Landry D, Moorhouse P, Tennankore KKJCJotASoN. Frailty and mortality in dialysis: evaluation of a clinical frailty scale. 2015;10(5):832–40.doi: https://doi.org/10.2215/CJN.07760814.

28.

van Loon IN, Goto NA, Boereboom FT, Bots ML, Verhaar MC, Hamaker MEJCJotASoN. Frailty screening tools for elderly patients incident to dialysis. 2017;12(9):1480–8.doi: https://doi.org/10.2215/CJN.11801116.

29.

Garcia-Canton C, Rodenas A, Lopez-Aperador C, Rivero Y, Anton G, Monzon T, et al. Frailty in hemodialysis and prediction of poor short-term outcome: mortality, hospitalization and visits to hospital emergency services. 2019;41(1):567–75.doi: https://doi.org/10.1080/0886022X.2019.1628061.

30.

Lee S-Y, Yang DH, Hwang E, Kang SH, Park S-H, Kim TW, et al. The prevalence, association, and clinical outcomes of frailty in maintenance dialysis patients. 2017;27(2):106–12.doi: https://doi.org/10.1053/j.jrn.2016.11.003.

31.

Yuan H, Zhang Y, Xue G, Yang Y, Yu S, Fu PJJoCN. Exploring psychosocial factors associated with frailty incidence among patients undergoing maintenance hemodialysis. 2020;29(9–10):1695–703.doi: https://doi.org/10.1111/jocn.15225.

32.

Song L, Zhao J, Ao Q, Cai X, Ma Q, Yang G, et al. Related factors of frailty in the elderly male patients with chronic kidney disease. 2019;99(40):3126–31.doi: https://doi.org/10.3760/cma.j.issn.0376-2491.2019.40.002

33.

Villarreal IR, Ortega O, Hinostroza J, Cobo G, Gallar P, Mon C, et al. Geriatric assessment for therapeutic decision-making regarding renal replacement in elderly patients with advanced chronic kidney disease. 2014;128(1–2):73–8.

34.

Chowdhury R, Peel NM, Krosch M, Hubbard REJAog, geriatrics. Frailty and chronic kidney disease: a systematic review. 2017;68:135–42.

35.

Chao CT, Hsu YH, Chang PY, He YT, Ueng RS, Lai CF, et al. Simple self-report FRAIL scale might be more closely associated with dialysis complications than other frailty screening instruments in rural chronic dialysis patients. 2015;20(5):321–8.

36.

Takeuchi H, Uchida HA, Kakio Y, Okuyama Y, Okuyama M, Umebayashi R, et al. The prevalence of frailty and its associated factors in Japanese hemodialysis patients. 2018;9(2):192.doi: https://doi.org/10.14336/AD.2017.0429.

37.

García-Cantón C, Ródenas Gálvez A, Lopez Aperador C, Rivero Y, Diaz N, Antón G, et al. Prevalencia de fragilidad y factores asociados en pacientes en programa de hemodiálisis. 2019;39(2):20Φ6.doi: https://doi.org/10.1016/j.nefro.2018.07.012.

38.

Jegatheswaran J, Chan R, Hiremath S, Moorman D, Suri RS, Ramsay T, et al. Use of the FRAIL Questionnaire in patients with end-stage kidney disease. 2020;7:2054358120952904.

Titel: Prevalence and Associates of Frailty Status in Different Stages of Chronic Kidney Disease: A Cross-Sectional Study
verfasst von: S. Ozturk
D. G. Cetin
M. Cetin
M. D. Yilmaz
T. E. Ozler
E. Cebeci
S. Karadag
H. Feyizoglu
Gulistan Bahat
Publikationsdatum: 17.09.2022
Verlag: Springer Paris
Erschienen in: The journal of nutrition, health & aging / Ausgabe 9/2022
Print ISSN: 1279-7707
Elektronische ISSN: 1760-4788
DOI: https://doi.org/10.1007/s12603-022-1839-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objectives

Design

Participants

Measurements

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Erratum to: Malnutrition Prolongs the Hospitalization of Patients with COVID-19 Infection: A Clinical Epidemiological Analysis

Iron Deficiency and Incident Infections among Community-Dwelling Adults Age 70 Years and Older: Results from the DO-HEALTH Study

Association of Homocysteine and Risks of Long-Term Cardiovascular Events and All-Cause Death among Older Patients with Obstructive Sleep Apnea: A Prospective Study

Association between the Lymphocyte-to-C-Reactive Protein Ratio and Survival Outcomes in Cancer Patients with GLIM-Defined Malnutrition: A Multicenter Study

Determinants of Resting Energy Expenditure in Very Old Nursing Home Residents